EyeTechCare has raised US$9 million
June 2010 — EyeTechCare has raised US$9 million, with funds provided by Lyon-based insurance company SHAM, a first time investor, and Crédit Agricole Private Equity (CAPE), one of EyeTechCare’s existing shareholders.
Founded in 2008 and based in Rillieux-la-Pape, near Lyon, France, EyeTechCare provides innovative medical non-invasive devices to permanently cure glaucoma, the first cause of blindness in developed countries.
The funds raised in this second financing will be used to complete the first clinical trial on humans, as well as establish the manufacturing facilities and the sales and marketing force required for this first product. The market launch is scheduled for early 2011.
Our role in the transaction
Oaklins’ team in France reviewed the strategy with the board and organized a fundraising with specialized venture funds.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
Learn more